Treatment costs of attention deficit hyperactivity disorder in Germany

Braun S, Zeidler J, Linder R, Engel S, Verheyen F, Greiner W (2013)
The European Journal Of Health Economics 14(6): 939-945.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ;
Abstract
Attention deficit hyperactivity disorder (ADHD) is one of the most common behavioural disorders among children and adolescents. The number of patients as well as prescriptions to treat this disease has continuously increased over the past few years. The aim of the present study was to analyse the costs for treating ADHD patients from the perspective of a major German health insurance fund. Anonymised administrative claims data were available for the study. All services reimbursed by the health fund for the selected ADHD patients were recorded. Apart from the resource use attributed directly to ADHD, co-morbidities as well as incremental costs were described based on a control group design. A total of 30,264 ADHD patients were diagnosed in 2008. The total costs for these patients were a,not sign3,888, and the incremental costs were a,not sign2,902. The largest proportions of incremental costs were due to therapeutic devices and remedies like occupational therapy amounting to a,not sign1,270. Proportionate costs of a,not sign263 have been settled for pharmacotherapy with Methylphenidate and Atomoxetine. However, 41 % of the patients were not treated with ADHD-related pharmaceuticals. ADHD costs are relevant from health insurance perspective. The expenses for occupational therapy constitute the cost driver. Compared to the findings of studies from the United States and contrarily to the backdrop of public discussions about considerably increased prescriptions of ADHD-specific drugs, the significantly higher additional expenses for occupational therapy services are impressing. This kind of therapy is internationally rather unknown and is therefore not acknowledged as a therapeutic standard.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Braun S, Zeidler J, Linder R, Engel S, Verheyen F, Greiner W. Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics. 2013;14(6):939-945.
Braun, S., Zeidler, J., Linder, R., Engel, S., Verheyen, F., & Greiner, W. (2013). Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics, 14(6), 939-945.
Braun, S., Zeidler, J., Linder, R., Engel, S., Verheyen, F., and Greiner, W. (2013). Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics 14, 939-945.
Braun, S., et al., 2013. Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics, 14(6), p 939-945.
S. Braun, et al., “Treatment costs of attention deficit hyperactivity disorder in Germany”, The European Journal Of Health Economics, vol. 14, 2013, pp. 939-945.
Braun, S., Zeidler, J., Linder, R., Engel, S., Verheyen, F., Greiner, W.: Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics. 14, 939-945 (2013).
Braun, Sebastian, Zeidler, Jan, Linder, Roland, Engel, Susanne, Verheyen, Frank, and Greiner, Wolfgang. “Treatment costs of attention deficit hyperactivity disorder in Germany”. The European Journal Of Health Economics 14.6 (2013): 939-945.
This data publication is cited in the following publications:
This publication cites the following data publications:

2 Citations in Europe PMC

Data provided by Europe PubMed Central.

Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis.
Klora M, Zeidler J, Linder R, Verheyen F, von der Schulenburg JM., Health Econ Rev 5(1), 2015
PMID: 26690366
[Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds].
Hoffmann F, Bachmann CJ., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(4), 2014
PMID: 24658675

26 References

Data provided by Europe PubMed Central.

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M., Curr Med Res Opin 23(8), 2007
PMID: 17588306

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 23179162
PubMed | Europe PMC

Search this title in

Google Scholar